ARTICLE | Company News
Macrocure plunges on Phase III futility analysis
August 21, 2015 1:09 AM UTC
Macrocure Ltd. (NASDAQ:MCUR) lost $9.07 (75%) to $2.98 on Thursday following its disclosure after market on Wednesday that a futility analysis showed CureXcell was unlikely to meet the primary endpoin...